Skip to content
    BRKR
    Earnings call· Mar 2026(Q1 FY26)

    BRUKER Q1 FY26 earnings call BRKR

    May 6, 2026 Source

    Executive summary

    Bruker Corporation Q1 FY26 — Strong Bookings and Cost Savings Drive Q1 Beat

    Bruker delivered Q1 FY26 results ahead of expectations, driven by strong BSI bookings momentum and effective cost-saving actions, despite a 4.4% organic revenue decline and significant margin headwinds. The company reconfirmed its full-year guidance, anticipating a return to organic revenue growth in Q2 and continued margin expansion, supported by AI-driven businesses and a stabilizing BEST segment. Management remains focused on cost control and innovation to navigate a dynamic macro environment.

    Highlights

    5

    • Q1 FY26 financial performance came in "well ahead of expectations" despite macro headwinds.

    • BSI segment organic bookings grew in the "high single digits" in Q1 FY26, with book-to-bill "comfortably above 1.0" for the third consecutive quarter.

    • AI-driven semiconductor metrology, SciY software, and European Middle East security detection businesses all saw organic bookings growth of "greater than 20%" in Q1 FY26.

    • BEST segment secured "$80 million" of multiyear orders for Fusion Technologies and "$600 million" of multiyear orders for high-performance superconductors.

    • Annualized cost savings are now tracking around "$140 million", exceeding the prior target of "$100 million to $120 million".

    Concerns

    6

    • Organic revenue declined "4.4%" year-over-year in Q1 FY26.

    • Non-GAAP gross margin decreased "130 basis points" to "50%" in Q1 FY26.

    • Non-GAAP operating margin decreased "250 basis points" to "10.2%" in Q1 FY26.

    • Q1 FY26 diluted non-GAAP EPS was "$0.31", down from "$0.47" in Q1 FY25.

    • China revenue declined "greater than 20%" organically year-over-year.

    • Continued pressure from U.S. academic demand, tariffs, and currency headwinds.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full Year 2026 Reported Revenue
    $3.57 billion to $3.60 billion
    high materiality
    High
    Full Year 2026 Organic Revenue Growth
    1% to 2%
    high materiality
    High
    Full Year 2026 Non-GAAP Operating Margin Expansion
    250 to 300 basis points
    high materiality
    High
    Full Year 2026 Organic Non-GAAP Operating Margin Expansion
    300 to 350 basis points
    high materiality
    High
    Full Year 2026 Non-GAAP EPS
    $2.10 to $2.15
    high materiality
    High
    Q2 2026 Organic Revenue Growth
    low to mid-single digits percentage
    medium materiality
    High
    Q2 2026 Non-GAAP Operating Margin
    meaningful year-over-year step-up
    medium materiality
    Medium
    Q2 2026 Non-GAAP EPS
    do better in the second quarter than we did sequentially on the first quarter of '26
    medium materiality
    Medium

    Segment performance

    5
    SegmentRevenueYoYQoQMargin
    BSI (Bruker Scientific Instruments)
    Book-to-bill ratio comfortably above 1.0 for the third consecutive quarter. Expected to return to organic revenue growth in Q2.
    Organic bookings growth: high single digits
    		—-5% organically——
    BEST (Bruker Energy & Supercon Technologies)
    Driven by superconducting wire business. Research instruments saw very strong orders. Orders from major MRI customers are for multiple years, stabilizing the segment for healthy single-digit organic growth.
    Multiyear orders for Fusion Technologies: $80 millionMultiyear orders for high-performance superconductors: $600 million (last 5 months)
    		—3% organically——
    BioSpin Group
    Revenue growth in preclinical imaging systems, Sywise software, and services business were more than offset by weakness in NMR systems due to soft ACO performance in China and Europe. Headwind from absence of gigahertz class systems in Q1 FY26 vs. Q1 FY25.
    		$198 millionhigh single-digits percentage CER decline——
    CALID Group
    Growth led by molecular spectroscopy and security detection orders. Microbiology and infection diagnostics had solid revenue growth. Life science mass spectrometry saw M&A contributions offset by U.S. academic weakness, but orders growth was positive.
    		$316 millionmid-single-digit percentage CER growth——
    Nano Group
    Strong revenue growth in semi metrology was more than offset by weakness in academic and industrial markets. Strong orders across the group, including tools for X-ray industrial research, spatial biology, high-bandwidth memory, and advanced packaging metrology, all driven by AI.
    		$246 millionmid-single digits percentage CER decline——

    Operational metrics

    32
    Reported Revenue
    $823.4 millionincreased 2.7% YoY
    Q1 FY26

    Reported revenue for the first quarter of 2026.

    Non-GAAP Gross Margin
    50%decreased 130 bps YoY
    Q1 FY26

    Inclusive of significant headwinds from foreign currency trends.

    Non-GAAP Operating Margin
    10.2%decreased 250 bps YoY
    Q1 FY26

    Inclusive of significant headwinds from foreign currency trends and partially offset by cost-saving actions.

    Non-GAAP Diluted EPS
    $0.31down from $0.47 in Q1 FY25
    Q1 FY26

    Meaningfully ahead of prior expectations, includes impact from MCP offering.

    GAAP Diluted EPS
    $0.02compared to $0.11 in Q1 FY25
    Q1 FY26

    Decline mostly due to lease impairment and restructuring charges related to cost-saving actions.

    Annualized Cost Savings Target
    $140 millionexceeding $100 million to $120 million target
    Annualized

    Tracking around $140 million in expected savings on an annualized basis. Majority of savings expected in H2 FY26 and beyond into FY27.

    Weighted Average Diluted Shares Outstanding
    152.7 millionincrease of 800,000 shares or 0.5% from Q1 FY25
    Q1 FY26

    Shares outstanding for the first quarter of 2026.

    Capital Expenditure Investments
    $24 million
    Q1 FY26

    Investments in capital expenditures.

    Cash and Cash Equivalents
    $133 million
    Q1 FY26 end

    Balance at the end of the first quarter.

    Debt Paydown
    $180 million
    Q1 FY26

    Deleveraging action, eliminating a Swiss franc-based term loan.

    Net Leverage Ratio
    2.9xdeclined
    Q1 FY26 end

    Net leverage ratio at the end of the first quarter.

    Semi Metrology Annual Revenue
    >$300 million
    Annual

    Now a greater than $300 million annual revenue business for Bruker.

    SciY Annual Revenue
    about $50 million
    Annual

    Now about a $50 million revenue business.

    Security Detection Annual Revenue
    about $70 million
    Annual

    Grown from a niche business a few years ago to about $70 million in revenue expected this year.

    Americas Revenue Growth
    low single digits percentage declineYoY organic basis
    Q1 FY26

    Organic revenue performance in the Americas.

    European Revenue Growth
    low single digits percentage declineYoY organic basis
    Q1 FY26

    Organic revenue performance in Europe.

    Asia Pacific Revenue Growth
    low double-digit percentage declineYoY organic basis
    Q1 FY26

    Organic revenue performance in Asia Pacific.

    China Revenue Growth
    greater than 20% declineYoY organic basis
    Q1 FY26

    Organic revenue performance in China, driven by weaker order demand in the prior year.

    EMEA Revenue Growth
    low single-digit percentageup
    Q1 FY26

    Organic revenue performance in EMEA.

    Systems Revenue Growth
    low double-digit percentage declineYoY organically
    Q1 FY26

    Systems revenue performance within the BSI segment.

    Aftermarket Revenue Growth
    high single-digits percentageYoY organically
    Q1 FY26

    Aftermarket revenue performance within the BSI segment.

    Academic Government Research End Market Revenue Growth
    double-digit declinesYoY organically
    Q1 FY26

    Organic revenue performance in the academic government research end market.

    Industrial End Market Revenue Growth
    double-digit declinesYoY organically
    Q1 FY26

    Organic revenue performance in the industrial end market.

    Semi End Market Revenue Growth
    organic revenue growth
    Q1 FY26

    Organic revenue growth in the semi end market.

    Biopharma End Market Revenue Growth
    organic revenue growth
    Q1 FY26

    Organic revenue growth in the biopharma end market.

    Hospital Clinical End Market Revenue Growth
    organic revenue growth
    Q1 FY26

    Organic revenue growth in the hospital clinical end market.

    BSI Organic Bookings Growth
    high single digitsYoY
    Q1 FY26

    Organic bookings growth for the Bruker Scientific Instruments segment.

    Academic Orders (ex-US) Growth
    double-digitYoY
    Q1 FY26

    Organic bookings growth for academic orders from outside the United States.

    Semi Metrology Organic Bookings Growth
    >20%YoY
    Q1 FY26

    Organic bookings growth for the AI-driven semiconductor metrology business.

    SciY Organic Bookings Growth
    >20%YoY
    Q1 FY26

    Organic bookings growth for the AI-driven SciY scientific software and lab digitization businesses.

    Security Detection Organic Bookings Growth
    >20%YoY
    Q1 FY26

    Organic bookings growth for the European Middle East security detection business.

    Life Science Mass Spec Orders Growth (US Academic)
    positiveYoY
    Q1 FY26

    Orders growth in U.S. academic life science mass spectrometry, indicating potential stabilization.

    Industry KPIs

    8
    MetricValueDetails
    Revenue EPS guidanceFY26 Reported Revenue: $3.57B-$3.60B (4%-5% growth); FY26 Organic Revenue Growth: 1%-2%; FY26 Non-GAAP EPS: $2.10-$2.15 (15%-17% growth)USD
    China revenue exposuregreater than 20% decline%
    Diagnostics testing demandsolid revenue growth
    M a contribution synergies2.6%%
    Segment organic revenue growthBioSpin: high single-digits percentage CER decline; CALID: mid-single-digit percentage CER growth; Nano: mid-single digits percentage CER decline; BEST: 3% CER growth%
    Bioprocessing orders book to billcomfortably above 1.0ratio
    Instruments vs consumables services mixSystems revenue declined low double-digit percentage; Aftermarket revenue grew high single-digits percentage%
    Organic core revenue growth by end market-4.4%%

    Product announcements

    3
    ProductTypeDetails
    NMR innovations (AI-driven protein NMR, Avance Neo console)launch
    CosMx system enhancementsupdate
    MyGenius Pro higher throughput systemlaunch

    Deals & partnerships

    2
    HitachiIntroduction of MyGenius Pro system in Japan using Bruker's molecular diagnostic assay.

    Hitachi is introducing Bruker's new MyGenius Pro higher throughput system in Japan, utilizing Bruker's molecular diagnostic assay for clinical microbiology.

    Major MRI customersMultiyear orders for high-performance superconductors.$600 millionmultiple years

    Bruker received approximately $600 million of multiyear orders for high-performance superconductors from all three major MRI OEM customers in the last 5 months (December through April).

    Risks & headwinds

    6
    U.S. academic demand weaknessQ1 FY26

    continued to pressure our year-over-year results

    Mitigation: Expects momentum once NIH funding environment improves; not banking on recovery for FY26 guidance.

    TariffsQ1 FY26, expected to ease in Q2 FY26

    continued to pressure our year-over-year results

    Mitigation: Expected to ease as company laps introduction of U.S. tariffs in Q2 FY25.

    Currency exchange rates (FX)Q1 FY26, expected to ease in Q2 FY26

    continued to pressure our year-over-year results

    Mitigation: Expected to ease as company laps significant depreciation of U.S. dollar in Q2 FY25.

    Lower volume and unfavorable mixQ1 FY26

    350 basis points headwind to operating margin in Q1 FY26

    Mitigation: Expects mix situation to improve through the rest of 2026.

    Geopolitical environmentOngoing

    dynamic macro... and geopolitical environment

    Mitigation: Prudent to confirm prior FY26 guidance; cost-cutting initiatives provide cushion.

    China revenue declineQ1 FY26

    greater than 20% decline in Q1 FY26

    Mitigation: Largely driven by weaker order demand in prior year; Q1 order performance was solid, showing improvement.

    What to watch in Q2 FY26

    5

    U.S. Academic Funding Recovery

    Q2 and Q3 FY26
    Currentbottomed or stabilized
    Targetpick up a little bit

    Why it matters

    Recovery in U.S. academic funding could provide upside to current guidance and drive future revenue.

    I'm somewhat optimistic that there will be a fair amount of funding between now and the end of the government fiscal year at the end of September and perhaps that will relate to good Q2 or Q3 orders.

    Q&A highlights

    5

    Inquired about the sustainability of strong OUS academic order growth and the aggregate contribution of niche markets like security detection and semi metrology to the portfolio.

    Frank Laukien stated that while the Q1 OUS academic order rate was exceptionally high and likely not sustainable at that exact level, high single-digit growth is expected. He noted that niche growth drivers (semi metrology, SciY, security detection) collectively represent "well above 10%" of the portfolio, moving the needle.

    “Yes, it's well above 10%, right? We haven't done that, but yes, a quick math would show that it's 10%, greater than 12%.”

    asked by Michail Paraskevopoulos · answered by Frank Laukien

    2 min read7 chapters

    Detailed Narrative

    01

    Q1 Performance Ahead of Expectations

    Bruker's Q1 FY26 financial performance exceeded internal expectations, despite facing significant macro and foreign exchange headwinds🌐. The organic revenue decline of 4.4% year-over-year was better than originally anticipated, demonstrating strong execution by the teams. This outperformance provides improved visibility and confidence for the remainder of the fiscal year.

    02

    Strong Bookings Momentum

    The BSI segment showed robust order trends, with organic bookings growing in the high single digits during Q1 FY26. This marks the third consecutive quarter where the BSI book-to-bill ratio was comfortably above 1.0, indicating sustained demand. Strength was observed in industrial research orders and encouraging double-digit academic order growth from outside the United States.

    03

    AI-Driven Growth Areas

    Bruker is capitalizing on the AI megatrend through several specialized businesses. Its semiconductor metrology business, now exceeding $300 million in annual revenue, saw over 20% organic bookings growth, driven by demand for memory chips and advanced packaging. Similarly, the SciY scientific software business, with approximately $50 million in annual revenue, also achieved over 20% organic bookings growth by providing lab digitization and AI-ready data solutions.

    04

    BEST Segment Turnaround

    The BEST segment experienced a significant turnaround, achieving 3% organic revenue growth net of intercompany eliminations. This was bolstered by substantial multiyear orders, including $80 million for Fusion Technologies and approximately $600 million for high-performance superconductors from major MRI customers over the last five months. These orders are expected to drive continued moderate organic growth for the segment.

    05

    Innovation and Product Launches

    Bruker introduced impactful new products and solutions across its portfolio. Key innovations include AI-driven advancements in protein NMR, making it more accessible, and a new Avance Neo console. In spatial biology, the CosMx system was enhanced with whole mouse transcriptome and high-plex proteomics. Additionally, the new MyGenius Pro higher throughput system was launched for clinical microbiology and molecular diagnostics.

    06

    Cost-Saving Initiatives

    The company's cost-out plan, referred to as the Bruker management process, is yielding substantial benefits. Annualized cost savings are now tracking at approximately $140 million, surpassing the initial target of $100 million to $120 million. The majority of these savings are expected to be reflected in the second half of FY26 and beyond, contributing significantly to margin expansion and EPS growth.

    07

    Geographic and End-Market Dynamics

    Geographically, Americas and European revenues declined in the low single digits organically, while Asia Pacific saw a low double-digit decline, primarily due to a greater than 20% drop in China revenue. However, China orders showed solid improvement in Q1. From an end-market perspective, organic revenue growth in semi, biopharma, and hospital clinical markets partially offset double-digit declines in academic government research and industrial markets.

    AI-generated summary of the company’s earnings call. Not investment advice.